Probiotic \u3ci\u3eBifidobacterium\u3c/i\u3e strains and
galactooligosaccharides improve intestinal
barrier function in obese adults but show
no synergism when used together as
synbiotics by Krumbeck, Janina A. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Publications in Food Science and
Technology Food Science and Technology Department
2018
Probiotic Bifidobacterium strains and
galactooligosaccharides improve intestinal barrier
function in obese adults but show no synergism
when used together as synbiotics
Janina A. Krumbeck
University of Nebraska-Lincoln, janina.krumbeck@gmail.com
Heather E. Rasmussen
University of Nebraska-Lincoln, heather.rasmussen@unl.edu
Robert W. Hutkins
University of Nebraska - Lincoln, rhutkins1@unl.edu
Jennifer L. Clarke
University of Nebraska-Lincoln, jclarke3@unl.edu
Krista Shawron
Rush University Medical Center
See next page for additional authorsFollow this and additional works at: http://digitalcommons.unl.edu/foodsciefacpub
Part of the Food Science Commons, Human and Clinical Nutrition Commons, Immunology and
Infectious Disease Commons, and the Molecular, Genetic, and Biochemical Nutrition Commons
This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska -
Lincoln. It has been accepted for inclusion in Faculty Publications in Food Science and Technology by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Krumbeck, Janina A.; Rasmussen, Heather E.; Hutkins, Robert W.; Clarke, Jennifer L.; Shawron, Krista; Keshavarzian, Ali; and Walter,
Jens, "Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no
synergism when used together as synbiotics" (2018). Faculty Publications in Food Science and Technology. 263.
http://digitalcommons.unl.edu/foodsciefacpub/263
Authors
Janina A. Krumbeck, Heather E. Rasmussen, Robert W. Hutkins, Jennifer L. Clarke, Krista Shawron, Ali
Keshavarzian, and Jens Walter
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/foodsciefacpub/263
RESEARCH Open Access
Probiotic Bifidobacterium strains and
galactooligosaccharides improve intestinal
barrier function in obese adults but show
no synergism when used together as
synbiotics
Janina A. Krumbeck1, Heather E. Rasmussen2, Robert W. Hutkins1*, Jennifer Clarke1, Krista Shawron3,
Ali Keshavarzian3* and Jens Walter1,4,5,6*
Abstract
Background: One way to improve both the ecological performance and functionality of probiotic bacteria is by
combining them with a prebiotic in the form of a synbiotic. However, the degree to which such synbiotic formulations
improve probiotic strain functionality in humans has not been tested systematically. Our goal was to use a randomized,
double-blind, placebo-controlled, parallel-arm clinical trial in obese humans to compare the ecological and
physiological impact of the prebiotic galactooligosaccharides (GOS) and the probiotic strains Bifidobacterium
adolescentis IVS-1 (autochthonous and selected via in vivo selection) and Bifidobacterium lactis BB-12 (commercial
probiotic allochthonous to the human gut) when used on their own or as synbiotic combinations. After 3 weeks
of consumption, strain-specific quantitative real-time PCR and 16S rRNA gene sequencing were performed on fecal
samples to assess changes in the microbiota. Intestinal permeability was determined by measuring sugar recovery in
urine by GC after consumption of a sugar mixture. Serum-based endotoxin exposure was also assessed.
Results: IVS-1 reached significantly higher cell numbers in fecal samples than BB-12 (P < 0.01) and, remarkably, its
administration induced an increase in total bifidobacteria that was comparable to that of GOS. Although GOS showed
a clear bifidogenic effect on the resident gut microbiota, both probiotic strains showed only a non-significant trend of
higher fecal cell numbers when administered with GOS. Post-aspirin sucralose:lactulose ratios were reduced in groups
IVS-1 (P = 0.050), IVS-1 + GOS (P = 0.022), and GOS (P = 0.010), while sucralose excretion was reduced with BB-12
(P = 0.002) and GOS (P = 0.020), indicating improvements in colonic permeability but no synergistic effects. No
changes in markers of endotoxemia were observed.
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Conclusion: This study demonstrated that “autochthony” of the probiotic strain has a larger effect on ecological
performance than the provision of a prebiotic substrate, likely due to competitive interactions with members of
the resident microbiota. Although the synbiotic combinations tested in this study did not demonstrate functional
synergism, our findings clearly showed that the pro- and prebiotic components by themselves improved markers
of colonic permeability, providing a rational for their use in pathologies with an underlying leakiness of the gut.
Keywords: Synbiotic, Probiotic, Prebiotic, Obesity, Gut barrier function, Autochthonous, Allochthonous,
Galactooligosaccharide, Bifidobacteria, Bifidobacterium
Background
It is now well established that the gastrointestinal (GI)
microbiota has a fundamental impact on metabolic, im-
munological, and endocrine functions of the host [1–4].
The host-microbe interrelationship is viewed as mutualis-
tic, contributing to overall host health [5]. However, aber-
rations in both microbiota composition and function can
result in the development of several chronic disease states
[6–8]. Obesity, in particular, is associated with a dysbiosis
characterized by low diversity and specific shifts in bacter-
ial taxa that correlate with metabolic and inflammatory
markers [9]. Although causation has not yet been estab-
lished in humans, these associations suggest that gut
microbes contribute to the subclinical systemic inflamma-
tion that ultimately lead to the development of pathologies
such as insulin resistance, type-2 diabetes, and cardiovas-
cular disease [10, 11]. One mechanism by which the gut
microbiota contributes to systemic inflammation is
through the translocation of pro-inflammatory and im-
munogenic bacterial compounds, including lipopolysac-
charide (LPS) and peptidoglycan, that can drive metabolic
endotoxemia [12, 13]. In fact, intestinal permeability has
been shown to be elevated in at least a subset of obese
subjects and is increased by high-fat diets, potentially con-
stituting a mechanism by which the microbiota contribute
to obesity [14]. The microbiome’s influence on both the
development of endotoxemia as well as intestinal barrier
integrity makes it a rational target for dietary strategies
aimed at reducing intestinal epithelial permeability and
obesity-associated pathologies.
Data from animal and in vitro studies suggest that
both specific bacterial taxa and their metabolic prod-
ucts influence intestinal barrier function. For example,
short-chain fatty acids produced from the fermentation of
non-digestible carbohydrates (including commonly used
prebiotics) have been reported to improve expression of
tight junction proteins, such as zona occludens proteins
(ZO-1-2), occluding, and claudin 1-4 (CLDN1-4) [15–19].
In addition, several studies suggest that probiotics, including
Bifidobacterium spp., Lactobacillus spp., and other lactic
acid bacteria, were associated with barrier function integrity
in vitro and in vivo [20–25]. In addition to strong associa-
tions between Bifidobacterium numbers and improvements
in intestinal epithelial cell barrier function and intestinal
permeability [12, 26, 27], functional studies have begun to
establish a causative role. For example, a strain of Bifidobac-
terium longum subsp. infantis (recently reclassified as Bifi-
dobacterium animalis subsp. lactis [28]) increased
trans-epithelial resistance and expression of tight junction
proteins in IL-10-deficient mice [29] and decreased intes-
tinal permeability in mice suffering from necrotizing entero-
colitis [30]. Furthermore, treatment with B. infantis and
Bifidobacterium bifidum decreased the gut endotoxin con-
centration in mice [31], and Bifidobacterium adolescentis
administration to rats significantly lowered rates of bacterial
translocation [32]. Bifidobacteria have also been associated
with metabolic improvements considered to be associated
with inflammation, including insulin sensitivity, white fat
accumulation, liver weight [33], reactive oxygen species, nu-
clear factor κB activation, and reduced markers of inflam-
mation [34], and high-density lipoprotein (HDL) plasma
cholesterol levels [35].
These findings provide a rational basis for the develop-
ment of strategies intended to enrich for Bifidobacterium
populations in the human gut. This can be achieved
through dietary consumption of probiotics and prebiotics.
The consumption of prebiotic carbohydrates, such as
galactooligosaccharide (GOS), resistant starch, fructooli-
gosaccharides (FOS), and inulin, have been shown to in-
crease autochthonous bifidobacteria in infants [36–38]
and adults [39–44]. However, the relative abundance of
resident Bifidobacterium levels in adults is highly variable,
ranging from 0 to 3% [45–48], and not all subjects
respond to prebiotic intervention, even at high doses [45,
46, 49, 50]. Therefore, one approach to enrich for bifido-
bacteria, increase the number of responders, and enhance
their metabolic activity would be to administer a prebiotic
together with a select probiotic Bifidobacterium strain or
strains that use the prebiotic as a growth substrate in vivo.
Such pairings are referred to as synergistic synbiotics [51].
According to ecological theory, the provision of resources
in a microbial community leads to a relaxation of compe-
tition [52, 53] and therefore could enhance colonization
success of probiotic strains [52, 53].
Several recent studies have reported improvements in
specific health biomarkers or outcomes after consumption
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of synbiotics [54–56]. Few studies, however, have sys-
tematically determined if synbiotics improve the eco-
logical attributes (such as establishment) and/or
enhance the health benefits of specific probiotics strains
compared to the probiotic alone [57–62]. Moreover, it
is currently unknown if it is possible for a probiotic
strain to benefit from the presence of a prebiotic sub-
strate in the competitive environment of the human
gut. Stable engraftment of an autochthonous B. longum
strain in the human gut was detected in subjects with an
apparent open niche based on resources [63], but it is un-
clear if such substrates can be administered by the diet. It is
also possible for prebiotics to exert microbiota-independent
effects [64–66].
We have recently developed a method for the selection
of autochthonous bacterial strains that are able to bene-
fit from prebiotic substrates in the competitive environ-
ment of the gastrointestinal tract [61]. This approach, in
vivo selection (IVS), is based on the identification of
bacterial strains that became enriched in human fecal
samples through the administration of a prebiotic com-
pound, providing a high likelihood that the strain can
preferentially utilize the substrate under the exact eco-
logical condition that prevail in the human gut. One
such strain, B. adolescentis IVS-1, was isolated from a
human subject, was unique to that subject, and grew
well on GOS [45, 61]. Remarkably, when B. adolescentis
IVS-1 was fed to rats, its relative abundance increased
from 3% in the absence of GOS to 37% when fed as a
synbiotic, i.e., in the presence of GOS [61]. The ability of
IVS-1 to expand more than tenfold, even in a different
host animal, suggested that this strain could be similarly
enriched in human subjects.
The primary goal of this study, therefore, was to
systematically compare the ecological and functional
properties of a rationally selected synergistic synbiotic
in a parallel-arm, placebo-controlled human trial.
Treatments included the human autochthonous strain,
B. adolescentis IVS-1, paired with its cognate prebiotic
(GOS), as well as a GOS synbiotic containing an alloch-
thonous commercial strain, B. animalis subsp. lactis
BB-12 [67]. The latter is known to utilize GOS in vitro
and indeed has a higher growth rate on GOS than on
glucose [68, 69]. This strain has also been combined
with GOS and used previously as a synbiotic in human
trials [70–72]. We also included treatments containing
only the probiotic strain or the prebiotic. This study de-
sign allowed us to assess the ability of the probiotic
strains to establish in the gastrointestinal tract, in the
presence and absence of GOS, and to identify their ef-
fects on microbiota composition. Clinical outcomes
were also assessed, with gut permeability as the primary
endpoint in a target group susceptible to a leaky gut
(obese individuals).
Methods
Subjects
This study was a randomized, double-blinded, placebo-
controlled, parallel-arm clinical trial conducted at Rush
University Medical Center (RUMC) in Chicago, USA.
Women and men between 18 and 65 years with a BMI
of 30.0–40.0 kg/m2 were recruited. Exclusion criteria
included the following: (1) prior intestinal resection; (2)
patient history of GI diseases except for hiatal hernia,
gastroesophageal reflux disease (GERD), and hemor-
rhoids; (3) severe renal disease defined by creatinine
more than twice normal; (4) markedly abnormal liver
function defined by ALT/AST over four times normal
levels or elevated bilirubin; (5) antibiotic use within the
last 12 weeks prior to enrollment; (6) lean or overweight
(BMI < 30.0 kg/m2), (7) intolerant to aspirin; (8) regular
use of aspirin; (9) excessive alcohol intake (more than two
drinks for men and one drink for women daily); (10) pres-
ence of chronic metabolic disease such as symptomatic
cardiovascular disease, insulin-requiring or uncontrolled
diabetes, current active treatment of cancer; (11) a plan to
have a major change in dietary habit during the following
6 months; (12) consumption of probiotics, prebiotics, or
synbiotics without an appropriate 2-week washout period;
(13) self-reported lactose intolerance; (14) subjects youn-
ger than 18 or older than 65; and (15) unwillingness to
consent to the study.
Study design
Four visits were required for each subject (Fig. 1a). At
visit 1, potential subjects were screened for eligibility
and provided written informed consent. Vitals and an-
thropometrics were completed, and blood was obtained
for endotoxin and metabolic markers. Subjects were
instructed to collect stool in anaerobic bags before visit
2 and deliver samples within 24 h if stored at − 20 °C or
within 5 h if stored at room temperature. At visit 2,
study subjects completed a 3-day food record and a
standardized 34-item GI symptom questionnaire (GSSC;
Gastrointestinal Symptom and Severity Checklist) to
identify potential impacts of treatment on GI symptoms,
including stool consistency, discomfort, flatulence, ab-
dominal pain, and bloating, on a scale from 0 (best) to 10
(worst). Within 1 week, subjects returned for visit 3 to
provide urine for baseline intestinal permeability measure-
ment, completed a blood draw, and were randomized to
one of the six treatments (see below). At the end of a
3-week treatment period, subjects returned to the clinic to
provide stool and urine samples and to complete a 3-day
food record to ensure consistency of dietary intake
throughout the study. A blood draw, anthropometrics,
and identical follow-up questionnaires were completed.
This study was approved by the Institutional Review
Board at RUMC in February of 2012, and all procedures
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were conducted according to the principles expressed in
the Declaration of Helsinki. This trial was registered at
clinicaltrials.gov, identifier NCT02355210.
Treatments
The prebiotic, GOS, was obtained from FrieslandCam-
pina, Amersfoort, the Netherlands (sold under the trade
name, Vivinal GOS powder) and contained 72.5% GOS,
22.8% lactose, and 4.7% monosaccharides (galactose and
glucose). It was previously established that a GOS dose of
5 g per day was sufficient to induce a bifidogenic response
[39]. Therefore, the total amount of GOS powder was
increased to 6.9 g to achieve a dose of 5 g GOS. An
additional 0.1 g of lactose was added to achieve the same
weight (7.0 g) as the other preparations.
The two probiotic strains used were B. adolescentis
IVS-1 [61] and B. animalis subsp. lactis BB-12. Strain
IVS-1 was produced from a contract manufacturer
(Danwell Technology, Garden Grove, CA) and provided
as a freeze-dried powder. Strain BB-12 was provided by
Chr. Hansen (Hørsholm, Denmark), also as a high cell
density freeze-dried powder. Its reported ability to fer-
ment GOS was confirmed in preliminary experiments
(data not shown). The probiotic powders were stored
for up to 6 months at − 18 °C, and viable cell numbers,
as determined by cultural enumeration, were shown to
a
b
Visit 2 
Collect: 
-Stool
-3-day food record
Complete:
-Questionnaires (GSSC)
Provide:
-Urine collection supplies
6am: 24-hr urine
Collect:
-Urine
Complete:
-Blood draw (endotoxin)
-Randomization to   
treatment
Provide:
-3-day food record
-Urine & stool   
collection supplies
-Treatment
Day:  -4       -3           -2         -1            
-12-hr fast
-6am: sugar cocktail
-6pm: 12-hr urine
-6am: 24-hr urine
-6pm: aspirin
-6am: sugar cocktail
-6pm: 12-hr urine
Visit 3
6am: 24-hr urine
Collect:
-Urine
-Stool
-3-day food record
Complete:
-Blood draw (endotoxin,  
CMP/CBC, lipids)
-Questionnaires (GSSC)
Visit 4Visit 1
* 2-week wash-out if consuming pro/prebiotics
Subjects collect stool & 
complete 3-day food 
record (no visit; 
Optional stool drop off)
Complete:
-Eligibility & consent
-Blood draw (endotoxin,  
CBC/CMP, lipids)
-Physical &   
Anthropometrics
Provide: 
-Stool kit
-3-day food record
Day:  -4       -3           -2         -1            
-12-hr fast
-6am: sugar cocktail
-6pm: 12-hr urine
-6am: 24-hr urine
-6pm: aspirin
-6am: sugar cocktail
-6pm: 12-hr urine
Fig. 1 Experimental design and participant flow diagram. a Time line for the human trial. Four visits were required from each subject. At visit 1,
potential subjects were screened for eligibility and provided with a 3-day food record, all supplies for stool and urine collection (stool kit, urine
collection containers, sugar cocktail, and aspirin), and instructions for specimen handling and for completing these tasks before the next visit.
Each subject collected stool before taking the sugar cocktail to avoid potential effects of sugar cocktail on microbiota composition. Details of the
stool and urine collection are shown. GSSC, Gastrointestinal Symptom and Severity Checklist. b Participant flow diagram showing the progress
through the phases of the randomized controlled trial (enrollment, intervention allocation, follow-up, and data analysis)
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be stable throughout the entire study period (data not
shown). Probiotic treatments were portioned into sachets,
each containing 0.1 g of probiotic powder (1010 CFU/g),
resulting in a daily dose of 1 × 109 CFU and 6.9 g of
lactose as a carrier/control. Synbiotics contained 6.9 g of
Vivinal and 0.1 g of probiotic (either B. adolescentis IVS-1
or B. animalis BB-12), for a total dose of 7.0 g. Placebo
samples contained 7.0 g of lactose.
The material was packaged in sachets in the Food
Processing Product Development Lab at the University of
Nebraska. The sachet material was impermeable to oxy-
gen and moisture. Subjects were provided with enough
sachets for the entire length of the 3-week treatment
period and were instructed to consume one sachet daily,
with 2 h between treatment and food consumption in
order to facilitate delivery of the probiotic/prebiotic com-
pounds into the cecum/large intestine by rapid emptying
of the compounds from the stomach and through small
bowel. Subjects were instructed to mix the treatment with
the provided bottled water only, as previous testing indi-
cated reduction in bacterial count of IVS-1 with tap water
(data not shown). All subjects were instructed to store
treatments in their freezer (− 18 °C).
Analysis of fecal microbiota
Fecal samples were stored in aliquots at − 80 °C until
further analysis. The DNA was extracted as previously
described [35]. Amplicon sequencing (Illumina MiSeq
platform v3 kit producing 300-bp paired-end se-
quences) was performed at the University of Minnesota
Genomics Center, with all samples being included in a
single run. The V5-V6 region of the 16S rRNA gene was
amplified using primer pair 784F (5′-RGGATTAGAT
ACCC-3′) and 1064R (5′-CGACRRCCATGCANCACC
T-3′). These primers were chosen based on our previous
findings that the V5-V6 region provided the best reso-
lution among Bifidobacterium species [61, 63], which we
considered the most important criteria for the aims of our
study. The 25-μl PCR mixtures contained 5 μl of template
DNA, 5 μl of 2× HotStarTaq PCR master mix, a final
concentration of primers of 500 nM, and 0.025 U μl−1
HotStarTaq polymerase (Qiagen Inc.), as previously de-
scribed [61]. The generated sequences were quality filtered
with Illumina software at the University of Minnesota
Genomics Center, resulting in more than 96% of the sam-
ples meeting all quality control criteria. Sequences that
did not meet quality filtering criteria were removed from
the analysis. All reads were trimmed to 240 base pairs
using the FASTX-Toolkit. The reads were merged and an-
alyzed for their sequencing depth. If a sample exceeded
37,000 reads, it was subsampled using Mothur v.1.31.162,
while samples that had less than 37,000 sequences were
left untreated. This normalization step was done as sug-
gested by Weiss et al. to account for differences in the
library size and minimize potential biases due to se-
quencing depth across samples [73]. Subsequently,
reads were filtered by length with a minimum of 240
base pairs and a maximum of 260 base pairs, derepli-
cated, OTU clustered, chimeras removed, and taxo-
nomically assigned as previously described [61]. After
processing and quality control, samples contained an
average of 22,487.59 ± 6683 sequences.
Quantitative real-time PCR (qPCR)
qPCR was performed by using a Mastercycler Realplex2
instrument (Eppendorf AG, Hamburg, Germany). Each
PCR was performed with 25-μl volumes using real-time
master mix containing SYBR (5 Prime Inc., Gaithersburg,
MD) and either genus-specific primers for Bifidobacter-
ium [39], or the strain-specific primers for B. adolescentis
IVS-1, as described previously [61]. Strain-specific PCR
for IVS-1 did not reveal products in baseline samples in
subjects of groups IVS-1 or IVS-1 +GOS or in the base-
line of another additional 20 randomly selected subjects
(data not shown).
For strain-specific detection of B. animalis subsp. lactis
BB-12, the PCR mixture contained 25 μl of PCR reaction
mix (QuantiFast® Probe PCR Kit, QIAGEN, Hilden,
Germany), 0.3 μmol of each primer (BAL-23S-F 5′-CA
GGTGGTCTGGTAGAGTATACCG-3′ and BAL-23S-R
5′-ACGGCGACTTGCGTCTTG-3′), 0.25 μmol of probe
(BAL-23S-P 5′-FAM-CGCCCACGACCCGCAAG-TAMR
A-3′), and 5 μl DNA as previously described [74]. The tar-
get of these primers and probe is the elongation factor Tu
(tuf) gene of BB-12. The specificity of the primers and
probe for BB-12 was validated experimentally by qPCR
using DNA from 11 different Bifidobacterium strains using
the same approach as described previously for the IVS-1
strain-specific qPCR [61]. These strains included B. adoles-
centis IVS-1, B. adolescentis ATCC 15703, B. adolescentis
L2-32, B. longum subsp. longum ATCC 15707, B. longum
DJO10A, B. longum ATCC 15697, B. longum subsp. longum
F8, B. longum subsp. longum JDM301, Bifidobacterium sp.
strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and
Bifidobacterium sp. strain HMLN14. Furthermore, primers
were tested against fecal DNA obtained from baseline fecal
samples from subjects in BB-12 and BB-12 +GOS groups,
and additional randomly selected samples from other sub-
jects. Strain BB-12 was detected in three out of 51 tested
subjects before the treatment was started, which may be
due to accidental consumption of food products containing
this strain.
Overall, we concluded that both qPCR assays were suffi-
ciently specific and that the test strains were either absent
or rare in the pre-treatment microbiota of the subjects.
Absolute quantification of both strains was achieved
through standard curves prepared by tenfold dilutions of
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DNA isolated from overnight cultures (14 h) for which
cell numbers were determined by quantitative culture.
Intestinal permeability
Subjects ingested a sugar mixture containing 2 g man-
nitol, 7.5 g lactulose, 40 mg sucrose, and 2 g sucralose
after a 12-h overnight fast (Fig. 1a). Subjects collected
urine into three separate containers for 5, 7, and 12 h,
for a total collection time of 24 h, in order to estimate
gastroduodenal permeability (5 h urinary sucrose),
proximal and distal small bowel permeability (5 h and
first 12 h urinary mannitol and lactulose and lactulose:-
mannitol ratio), and total and primarily colonic perme-
ability (24 h urinary sucralose level and sucralose/
lactulose ratio) as we previously described [75]. Com-
pared to normal-weight individuals, obese individuals
are more likely to have a hyper-permeable intestine
[76]. However, values vary greatly among individuals,
and a treatment with aspirin has been shown to im-
prove consistency in intestinal permeability measure-
ments [76, 77]. Therefore, the subjects participated in
an aspirin challenge consuming four 325-mg aspirin
tablets both 12 h before and immediately before inges-
tion of the sugar mixture. Thus, urine was collected for
two separate 24-h periods with and without aspirin
treatment, and both before and after treatment. Urine
was analyzed for concentrations of mannitol, lactulose,
and sucralose using gas chromatography (GC). Intes-
tinal permeability was expressed as a percent of the
oral dose excreted in the urine.
Plasma and serum measures of endotoxin exposure
Serum endotoxin (LPS) and LPS-binding protein (LBP)
were measured after the aspirin challenge both before and
after treatment. Endotoxin was measured in serum by
Limulus Amebocyte Lysate QCL-1000 (Lonza # 50-647U).
Serum samples were diluted at a 1:5 ratio with LAL re-
agent water. LBP was measured in plasma using an ELISA
kit from Cell Sciences Inc. (# HK315).
Serum metabolic markers
A complete metabolic panel and complete blood count
were performed to allow an assessment of treatment safety.
To assess impact of treatments on metabolic markers, a
lipid panel was completed by Quest Diagnostics and in-
cluded the following: total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), and triglycerides. Non-HDL was cal-
culated by subtracting HDL-C from TC.
Vitals and anthropometrics
Blood pressure was measured using an automated cuff
with the average of three assessments used for statistical
comparisons. Body weight and waist circumference was
assessed and BMI calculated before and after treatment.
Statistical analysis
All data presented was analyzed based on a per protocol
analysis. Subjects were excluded from the analysis if the
study protocol was not followed, including use of antibi-
otics during the treatment period, storage of the treat-
ments at room temperature, and use of tap water to
consume treatments. Data is presented as mean ± SEM
for variables that were normally distributed, or median
(IQR) for variables not normally distributed. Group means
were compared by ANOVA and post hoc tests except
when data were not normally distributed, in which case a
nonparametric analysis of medians was performed using
the Kruskal-Wallis test. Chi-square tests or Fisher’s exact
tests were used for incidence data. If only two groups were
compared, Student’s t tests were performed.
For the analysis of the gut microbiota, Mann-Whitney-
Wilcoxon matched pair tests were used for pairwise
comparisons between time points for the 16S rRNA gene
sequencing and qPCR data, as data was normally distrib-
uted. Unpaired Mann-Whitney-Wilcoxon tests were used
for pairwise comparisons between treatment groups. When
more than two samples were compared, Kruskal-Wallis test
was applied. P values were corrected for the total number
of comparisons with the use of a false-discovery rate (FDR)
method in R, whereby values were considered significant
for FDR-adjusted P values (reported as Q values) of < 0.1.
Results
Subject enrollment
A total of 151 volunteers were enrolled in the study
(Fig. 1b). Of these, 114 subjects were randomly assigned
to the six treatments, and 94 were used in the analyses
after accounting for attrition and excluding for protocol
deviation.
Baseline demographic and clinical characteristics
The majority of the subject cohort was female (71%), mid-
dle aged (44.3 ± 11.2 [mean ± SD]), non-Hispanic or La-
tino (90.4%), and of African American ethnicity (61.7%)
(Additional file 1: Table S1). All subjects were obese, with
a median (IQR) BMI of 36.7 (8.5) kg/m2 and waist circum-
ference of 45.0 ± 7.3 in. Other clinical metabolic markers
were within the normal range (Additional file 1: Table S1).
Randomization resulted in all demographic and clinical
characteristics, including race, ethnicity, systolic/diastolic
blood pressure, cholesterol (total, LDL, HDL, non-HDL),
glucose, and triglyceride, to not differ significantly be-
tween groups with one exception: the IVS-1 + GOS group
had a higher BMI (P = 0.049) when compared to the
IVS-1 group (Additional file 1: Table S1).
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Safety and tolerability of treatments and impact on
dietary patterns
No differences in complete metabolic panel and complete
blood count values were observed with any treatment (data
not shown). Mild gastrointestinal symptoms are common
among heathy obese adults, and many study participants
reported bloating (60.6%), passing gas (85.1%), hard stools
(46.8%), and watery stools (43.6%) at baseline. No signifi-
cant differences in median symptom score were detected
between the six groups at baseline (Additional file 1: Table
S2). Treatments were generally well tolerated with minimal
reported side effects. The GOS group had significantly
harder stools when compared to the BB-12 +GOS group
(P = 0.024). Passing gas increased from a median of 2.5 to
5.0 with lactose supplementation, potentially because of un-
declared lactose intolerance, but this was not significantly
different between baseline and treatment end (P = 0.150).
The “severity of passing gas” was significantly reduced from
4.0 to 1.0 in the BB-12 +GOS group (comparison of base-
line to treatment; P = 0.040), and severity of hard stools in-
creased from 1.0 to 3.5 (on a score from 1 to 10) in the
GOS group (P = 0.030). No differences in macronutrient or
micronutrient intake were detected before and after the
treatment period, suggesting treatment tolerability was not
influenced by dietary intake (data not shown).
Cell numbers of strains IVS-1 or BB-12 in fecal samples
Strain-specific qPCR revealed that both strains reached
significantly higher cell numbers during the treatment
period when compared to the baseline samples (P < 0.001
in group IVS-1 +GOS; P < 0.0007 in groups IVS-1, BB-12,
and BB-12 +GOS) (Fig. 2a). IVS-1 was detectable at an
average of 6.99 ± 1.2 log10 and 7.22 ± 1.6 log10 of cells g
−1 in
the IVS-1 and IVS-1 +GOS groups, respectively. BB-12
was detected at absolute numbers of 5.83 ± 0.7 log10 and
6.11 ± 0.7 log10 cells g
−1 in the BB-12 and BB-12 +GOS
groups, respectively. Comparisons of cell numbers of the
probiotic strains among treatments (Fig. 2b) revealed that
IVS-1 was detected at significantly higher numbers in fecal
samples than BB-12 in both probiotic-only treatments (P =
0.0056), and when GOS was added (P = 0.0127). Although
GOS led to a modest increase in cell numbers of both
strains when compared with the probiotic-only groups
(Fig. 2b), this increase did not reach statistical significance
(P = 0.6682 and P = 0.3034, respectively).
Impact of treatments on total number of bifidobacteria in
fecal samples
Genus-specific qPCR was used to determine total fecal
bifidobacteria in all six groups (Fig. 3a). There was no
significant difference in the numbers of Bifidobacterium
in the baseline samples between groups. Among the pro-
biotic treatments, only IVS-1 administration led to an in-
crease in the total number of bifidobacteria (P = 0.0017).
Significant increases were also detected for all three
groups containing GOS when compared to baseline,
confirming the bifidogenic effect of GOS that has been
observed in previous human studies [40, 41, 45, 78–80].
a b
Fig. 2 Quantification of probiotic strains in fecal samples by qPCR. a Quantification of absolute cell numbers of probiotic strains in fecal samples
by strain-specific qPCR. Shown are probiotic and synbiotic treatment groups at baseline and treatment time points. Significance of P ≤ 0.05 is
denoted by a single asterisk (*), P ≤ 0.01 by two asterisks (**), and P≤ 0.001 by three asterisks (***). b Direct comparison of absolute abundances
of B. adolescentis IVS-1 and B. animalis subsp. lactis BB-12 at each time point using strain-specific qPCR. Different letters indicate significant
differences between groups (P ≤ 0.05)
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There was no significant difference in the average
numbers of Bifidobacterium between treatment groups
at the end of the treatment period (Fig. 3b). However,
the Bifidobacterium numbers at the baseline varied
greatly between individuals within each group, ranging
from the detection limit (log10 4.7 cells g
−1 feces) to a
maximum of 10.4 log10 cells g
−1 feces. In addition, a
large variation in the increase in total bifidobacteria
was detected among participants (Fig. 3a), suggesting
an individualized response to the treatments in all six
groups. Therefore, the absolute changes in Bifidobacter-
ium cell numbers for individual subjects were calcu-
lated and these shifts compared among the six groups
(Fig. 3c). Although there were no significant differences
(P = 0.2071), the highest increases in Bifidobacterium
numbers were found in the IVS-1 group with 1.43 ± 1.6
log10, followed by the GOS group with 1.30 ± 1.7 log10.
Interestingly, the lactose group also showed a modest
increase in bifidobacteria (0.50 ± 1.0 log10).
Characterization of the fecal microbiota by 16S rRNA
gene sequencing
Illumina sequencing of 16S rRNA gene amplicons was
used to determine the effect of the treatments on the
overall bacterial community in fecal samples. This ana-
lysis revealed that the treatments did not exert a
community-wide effect on the resident gut microbial com-
munity: Both alpha- and beta-diversity were compared
between time points within each group, and across all
six groups for both time points, but no differences
were detected for any of the comparisons (P > 0.05,
data not shown).
Illumina sequencing, however, did show that the relative
abundances of specific taxa were affected by treatments.
In particular, the phylum, Actinobacteria, were signifi-
cantly higher in subjects treated with IVS-1 (P = 0.0072,
Q = 0.0316), IVS-1 + GOS (P = 0.0015, Q = 0.0176), BB-12
+ GOS (P = 0.0279, Q = 0.0516), GOS (P = 0.0468, Q =
0.0722), and lactose (P = 0.0526, Q = 0.0794) (Table 1). At
the genus level, the relative abundance of Bifidobacterium
was increased in groups IVS-1 (P = 0.0138, Q = 0.0420),
IVS-1 +GOS (P = 0.0039, Q = 0.0253), BB-12 + GOS (P =
0.0140, Q = 0.0420), and GOS (P = 0.0686, Q = 0.0991).
The most significant and consistent shifts were de-
tected among the operational taxonomic units (OTUs)
that represented the probiotic strains. The OTU with an
identical sequence to B. adolescentis IVS-1 (OTU_1) was
significantly enriched in groups IVS-1 (P = 0.0010, Q =
0.0176) and IVS-1 + GOS (P = 0.0176, Q = 0.0476), indi-
cating that this OTU was primarily enriched through the
administration of the probiotic (although non-significant
increases were also detected for the GOS and lactose
groups). Mann-Whitney test between groups IVS-1 and
IVS-1 + GOS showed that IVS-1 + GOS had a signifi-
cantly higher relative abundance of OTU_1 than IVS-1
(P = 0.0146), suggesting a functional synergism between
a
b
c
Fig. 3 Absolute quantification of total bifidobacteria by qPCR. a Quantification of absolute cell numbers of total bifidobacteria in fecal samples
by genus-specific qPCR. b Direct comparison of abundances of genus Bifidobacterium at the treatment time point using genus-specific qPCR.
c Change in abundance of bifidobacteria for each subject with treatment consumption
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Table 1 Proportions of bacterial taxa (with > 0.1% in at least one of the treatments) significantly influenced by dietary treatments
within treatment groups (FDR-adjusted P value < 0.1). Significant values are set in italics
Treatment
Taxonomic group Baseline Treatment P value Q value
(FDR adjusted)
IVS-1 Phylum
Actinobacteria 9.106 ± 5.25 15.422 ± 5.98 0.0072 0.0316
Genus
Bifidobacterium 7.605 ± 7.41 14.565 ± 6.92 0.0138 0.0420
OTUsa
OTU_1 (B. adolescentis) 1.199 ± 4.24 3.403 ± 5.08* 0.0010 0.0176
OTU_167 (B. animalis subsp. lactis) 0.001 ± 0.00 0.001 ± 0.00 1.0000 1.0000
OTU_7 (B. adolescentis or ruminantium) 0.817 ± 2.24 1.916 ± 4.33 0.0291 0.0516
Bb 12 Phylum
Actinobacteria 10.660 ± 5.17 11.886 ± 7.68 0.9051 0.9540
Genus
Bifidobacterium 8.796 ± 5.70 9.450 ± 8.39 0.8782 0.9514
OTUsa
OTU_1 (B. adolescentis) 1.237 ± 2.46 1.160 ± 1.62 0.7787 0.8814
OTU_167 (B. animalis subsp. lactis) 0.034 ± 0.04 0.055 ± 0.05 0.0073 0.0316
IVS-1 GOS Phylum
Actinobacteria 8.129 ± 4.79 15.780 ± 7.11 0.0015 0.0176
Genus
Bifidobacterium 5.959 ± 5.88 14.650 ± 7.44 0.0039 0.0253
Anearotrunctus 0.048 ± 0.09 0.010 ± 0.01 0.0236 0.0511
Roseburia 3.379 ± 1.64 1.825 ± 1.15 0.0018 0.0176
OTUsa
OTU_1 (B. adolescentis) 2.476 ± 4.49 7.344 ± 7.00* 0.0176 0.0476
OTU_167 (B. animalis subsp. lactis) 0.001 ± 0.00 0.003 ± 0.01 1.0000 1.0000
OTU_102 (Lachnospiracea incertae sedis) 0.352 ± 0.49 0.070 ± 0.16 0.0100 0.0390
OTU_152 (Alistipes) 0.176 ± 0.36 0.013 ± 0.05 0.0463 0.0722
Bb 12 GOS Phylum
Actinobacteria 11.665 ± 5.90 17.034 ± 6.51 0.0279 0.0516
Genus
Bifidobacterium 8.862 ± 6.15 15.86 ± 7.97 0.0140 0.0420
Anaerovorax 0.295 ± 0.09 0.18 ± 0.09 0.0283 0.0516
OTUsa
OTU_1 (B. adolescentis) 3.138 ± 4.53 6.797 ± 9.61 0.0812 0.1131
OTU_167 (B. animalis subsp. lactis) 0.003 ± 0.001 0.112 ± 0.18 0.0006 0.0176
OTU_156 (Clostridium XI) 0.151 ± 0.20 0.071 ± 0.21 0.0345 0.0585
GOS Phylum
Actinobacteria 13.923 ± 8.98 18.067 ± 9.78 0.0468 0.0722
Genus
Bifidobacterium 11.329 ± 10.48 17.358 ± 11.41 0.0686 0.0991
Bacteroides 5.794 ± 4.43 2.854 ± 4.11 0.0121 0.0420
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the synbiotic components IVS-1 and GOS. Similar syn-
ergism was not detected for OTU_167 representing B.
animalis subsp. lactis BB-12 in the BB-12 and GOS
groups (P = 0.6895). However, this OTU was still signifi-
cantly increased in both groups when compared to base-
line. It was also mostly undetectable in groups that did
not receive BB-12 (confirming its allochthonous status
in the human gut).
Interestingly, the enrichment of OTU_1 with GOS
showed associations with other members of the Bifido-
bacterium population. An analysis of individuals that
had no, or only a low increase of OTU_1 (calculated as
relative abundance of OTU_1 of total Bifidobacterium
rather than of total bacteria) in groups IVS-1 and
IVS-1 + GOS at baseline (non-responders), showed that
these subjects had one of six other Bifidobacterium
OTUs to be dominant at baseline. The six identified
OTUs included OTU_7 (B. adolescentis or ruminantium),
OTU_10 (B. longum), OTU_2055 (B. pseudocatenulatum),
OTU_2111 (Bifidobacterium sp.), OTU_2202 (B. pseudo-
catenulatum), and OTU_438 (B. pseudocatenulatum).
These OTUs are related to OTU_1 (Additional file 2:
Figure S1). None of these six OTUs correlated signifi-
cantly with OTU_1 when analyzed on their own. However,
the sum of the six OTUs correlated negatively with the
relative abundance of OTU_1 at the end of the treatment
period (P = 0.0313, R = − 0.4005), indicating competition
between these taxa and OTU_1 for the substrate GOS.
Few other changes were detected. We tested an effect of
the treatments on specific features of the microbiota that
have been suggested to be relevant for health. The ratio
between Prevotella and Bacteroides, which has been re-
ported to be influenced by dietary treatments and
long-term dietary patterns [81, 82] and relevant for
metabolic health [81, 83], was not different within
treatment groups or when groups were compared (data
not shown). Additionally, the relative abundance of bu-
tyrate producing genera such as Faecalibacterium, Eubac-
terium, Roseburia, Lachnobacterium, and Ruminococcus
was analyzed. IVS-1 + GOS supplementation significantly
decreased the relative abundance of Roseburia (Table 1).
We also analyzed the shift in relative abundances (treat-
ment value minus baseline value) and saw a significant
reduction of Lachnobacterium (P < 0.0001) in the GOS
group (data not shown).
Impact of treatments on intestinal permeability and
endotoxemia
To determine the effect of the treatments on intestinal
permeability, urine sugar excretion after consumption of a
sugar cocktail was compared in pre-treatment samples
versus samples taken after the interventions, and LPS and
LBP levels were determined in serum. At baseline, no sig-
nificant differences in gastrointestinal permeability existed
between the groups (P > 0.4, data not shown). No differ-
ences in percent change in intestinal permeability were
detected between the groups after treatment (inter-group
comparisons; Additional file 1: Table S3). When differ-
ences in absolute permeability were examined before and
after treatment by intra-group comparisons, there were
Table 1 Proportions of bacterial taxa (with > 0.1% in at least one of the treatments) significantly influenced by dietary treatments
within treatment groups (FDR-adjusted P value < 0.1). Significant values are set in italics (Continued)
Treatment
Taxonomic group Baseline Treatment P value Q value
(FDR adjusted)
OTUsa
OTU_1 (B. adolescentis) 3.793 ± 7.47 6.645 ± 8.83 0.1221 0.1587
OTU_167 (B. animalis subsp. lactis) 0.000 ± 0.00 0.203 ± 0.85 0.4504 0.5489
Lactose Phylum
Actinobacteria 10.471 ± 6.75 14.502 ± 6.89 0.0529 0.0794
Genus
Bifidobacterium 7.895 ± 8.10 12.008 ± 8.02 0.0917 0.1233
OTUsa
OTU_1 (B. adolescentis) 1.241 ± 1.93 2.557 ± 4.11 0.6562 0.7755
OTU_167 (B. animalis subsp. lactis) 0.000 ± 0.00 0.037 ± 0.14 0.7910 0.8814
OTU_315 (Coprobacillus) 0.100 ± 0.09 0.062 ± 0.06 0.0023 0.0179
OTU_43 (Ruminococcus2) 0.562 ± 0.75 0.272 ± 0.63 0.0051 0.0284
OTU_180 (Bacteroides) 0.041 ± 0.17 0.127 ± 0.40 0.0183 0.0476
aIf the strain could not be assigned to a type strain (< 97% homology), RDP Classifier was used to determine the most likely genus (80% cutoff)
*Significant difference between the two treatment groups for OTU_1
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significant reductions in permeability for the post-aspirin
sucralose:lactulose ratio in groups IVS-1 (P = 0.050),
IVS-1 +GOS (P = 0.022), and GOS (P = 0.010) (Fig. 4a).
Additionally, there was a significant reduction in the
post-aspirin excretion of sucralose in groups BB-12
(P = 0.0020) and GOS (P = 0.0171) (Fig. 4b). Perme-
ability in the absence of an aspirin challenge was not
affected (data not shown).
Baseline markers of endotoxemia did not differ
between groups (P > 0.05). There were no significant ef-
fects of any treatment on serum LPS and LBP levels
(P > 0.05, Additional file 1: Table S4). Minimal changes
were seen in both anthropometrics and metabolic
markers; the only significant difference was seen be-
tween a median increase in HDL-cholesterol in the
BB-12 + GOS (3.7 [15.9]) group and a decrease in the
BB-12 group (− 3.8 [13.2]) (P = 0.032, Additional file 1:
Table S5).
Discussion
In this study, we characterized both the ecological im-
pact and physiological effect of two synbiotic combina-
tions, each composed of a Bifidobacterium strain and
the prebiotic GOS, with each other and with their pro-
biotic and prebiotic components. Despite the rational
for the synbiotic approach, establishing synergism (eco-
logical or functional) has been challenging for several
important reasons [62]. First, most probiotic/prebiotic
combinations have been designed and formulated with-
out having demonstrated synergism under the competi-
tive conditions of the gastrointestinal tract. Second,
rarely has the experimental design of studies included
individual probiotic and synbiotic treatments. Finally,
most synbiotic studies used techniques that did not
allow for a quantification of the probiotic strain. In this
study, we compared synbiotic products comprised of ei-
ther an in vivo selected autochthonous or an allochthon-
ous strain, each paired with GOS and tested by itself, and
included a qPCR analysis with strain level resolution to
quantify the probiotic strains.
Consistent with ecological theory [53], the autoch-
thonous strain IVS-1 had a clear ecological advantage
over the allochthonous strain BB-12 in that it could be
established at about tenfold higher cell numbers. In
addition, administration of IVS-1 increased cell numbers
of total bifidobacteria as well as the proportion of the
genus Bifidobacterium and the phylum Actinobacterium.
Such enrichments of higher taxonomic groups through
the administration of probiotic bifidobacteria has, to our
knowledge, not been previously shown and is remarkable
given that the human gut contains high level of resident
bifidobacteria and Actinobacteria. In contrast, the al-
lochthonous strain BB-12, although detectable at low
levels with 16S rRNA gene sequencing, did not increase
a b
Fig. 4 Intestinal permeability after an asperin challenge as inferred by measuring the a sucralose:lactulose ratio and b concentration (as percent
of oral dose) in urine before and after the pro-, pre-, and synbiotic treatments. To assess intestinal permeability, urine was collected for 24 h after
the subjects had consumed a sugar cocktail together with aspirin and analyzed by gas chromatography
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total bifidobacteria. Overall, the findings support the
concept that autochthonous members of the microbiota
would be substantially more successful when introduced
into the human gut [53, 63].
The findings on the ability of GOS to support the pro-
biotic strains were more subtle. The OTUs that repre-
sented the two probiotic strains (OTU_1 and OTU_167)
were higher in the synbiotic groups when compared to
the probiotic groups alone, with findings reaching sig-
nificance for OTU_1 (Table 1). However, cell numbers
of both IVS-1 and BB-12 were only marginally and not
significantly increased through GOS (Fig. 2). We there-
fore conclude that although there was a consistent in-
crease in the probiotic strains in the synbiotic groups,
inter-individual variability was likely too high to achieve
significant findings with the number of subjects in this
study. Our findings further suggest that ecological inter-
actions with the resident microbiota but also the specific
manner in which the synbiotic preparations were formu-
lated (e.g., all included lactose, and GOS doses were all
at 5 g) could explain the limited synergism that we
observed.
The analysis of the whole gut bacterial community by
16S rRNA gene sequencing not only provided insights
into the effect of the treatments on overall microbiota
composition, but also suggested a possible reason for the
limited synbiotic effect that we observed. Overall, the ef-
fect of the treatments on gut microbiota composition was
remarkably specific, increasing mainly total bifidobacteria
and the specific OTUs that represented the probiotic
strains, while a limited number of other taxa were de-
creased (Table 1). In agreement with our previous study
[45], the most significant increase induced by GOS was in
the genus Bifidobacterium, which occurred in all groups
receiving GOS, including the groups that did not receive
the probiotic strains. This finding clearly establishes that
resident members of the gut microbiota are able to utilize
GOS, likely competing with the ingested probiotic strains
for the substrate. Accordingly, the OTU representing
IVS-1 (OTU_1) correlated negatively with the sum of
dominant Bifidobacterium OTUs during treatment with
GOS, suggesting competition for the substrate. Given that
the gut microbiota is highly specific to an individual, it is
likely that resident strains have a higher affinity to GOS
compared to the incoming strain even if the latter is au-
tochthonous to humans, as it is still foreign to the micro-
biota of that specific subject.
Another reason for the limited synergistic effect of GOS
might be that the Bifidobacterium strains in the “probiotic
only” powders were given as a mixture with lactose, which
also served as the placebo in this study. The rational for
that choice was that the GOS is synthesized from lactose
and contained 22.8% lactose in the powder that was ad-
ministered. We further reasoned that lactose would be
hydrolyzed and absorbed in lactose-tolerant individuals
before it reaches the colon [84]. However, in subjects with
insufficient expression of the LCT gene (encoding for lac-
tase) [85, 86], lactose can become a “conditional prebiotic”
[87] and serve as a colonic substrate for bifidobacteria,
which are well equipped to metabolize lactose [88, 89].
While our study subjects self-reported to be lactose toler-
ant, both the qPCR and amplicon sequencing analyses
showed that lactose supplementation did lead to a
non-significant and highly personalized increase in the
average relative abundance of bifidobacteria. Indeed, seven
of the 17 subjects in the lactose group had increases of
bifidobacteria of more than 0.50 log10 (Fig. 3c). Interest-
ingly, six of these seven “responders” self-identified as
African American, who are more likely to carry LCT genes
that predispose them to lactose malabsorption [85, 86].
A mild form of lactose malabsorption was indeed sug-
gested among our subjects by the non-significant increase
in passing gas in the lactose group (Additional file 1: Table
S5). Therefore, a combination of the “conditional prebiotic”
effect of lactose, the ability of the resident microbiota to
compete for GOS, and the substantial inter-individual vari-
ation might have lowered our ability to detect a more pro-
nounced impact of GOS on establishment of the probiotic
strains.
We chose intestinal barrier function as the primary out-
come of the human trial because of its importance in the
prevention of inflammation not only in metabolic diseases
but also in gastrointestinal and systemic inflammatory
disorders such as inflammatory bowel disease [90],
non-alcoholic steatohepatitis (NASH) [91], and Parkinson
disease [92]. In our study, no treatments significantly im-
pacted markers of intestinal permeability in non-aspirin
treated subjects. However, when susceptibility to intestinal
hyperpermeability was increased through a high-dose of
aspirin, permeability was reduced with both probiotic
treatments and with GOS intake. While no overall
changes in the microbial community were seen, as mea-
sured by alpha- and beta-diversity, the enrichment in bifi-
dobacteria common to all of these treatments might be
associated with this decrease, and both the autochthonous
and the allochthonous probiotic strain showed an effect.
As markers of small bowel permeability (5-h urinary lactu-
lose or mannitol; data not shown) were not reduced, the
treatment effects appear to be primarily directed to per-
meability of the colon [75], the site where the majority of
bacteria, including bifidobacteria, reside. Overall, our
findings are in agreement with observations in rodents
that showed that GOS [93], B. adolescentis [32], and B.
animalis subsp. lactis CNCM-12494 [94, 95] improved in-
testinal permeability. In accordance with the findings from
the gut microbiota analysis, there was no evidence for
synergism in the synbiotic treatments in respect to perme-
ability. Indeed, although permeability (based on sucralose
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excretion) was improved for both the BB-12 and GOS
treatments, the BB-12 + GOS treatment was not im-
proved. It is possible that the effect was muted when both
were present, or that an antagonistic event had occurred,
similar to that recently described by Schroeder et al. [96],
where mucus permeability was improved by inulin, but
not by inulin plus B. longum.
Despite the detectable improvement in intestinal per-
meability, no significant effects on serum endotoxin or
metabolic outcomes were seen with any synbiotic, prebi-
otics, or probiotic treatment. While promising, limited
evidence exists to support the use of GOS [97] and bifi-
dobacteria [98] supplementation for serum LPS reduc-
tion. In contrast, a synbiotic comprised of Lactobacillus
plantarum and FOS was recently shown to significantly
reduce sepsis in infants [55]. In other studies, improve-
ments in metabolic markers with GOS intake [41] have
been observed, but the impact on metabolic outcomes
with bifidobacteria intake is uncertain. Bifidobacteria cell
counts were increased through IVS-1 + GOS; however,
changes in bifidobacteria are not always associated with
improvements in LPS [99] or metabolic markers [100]. It
is possible that the treatment duration of 3 weeks was
not long enough for metabolic improvements to become
evident, or that serum concentrations of these markers
were not at high enough concentrations to see a mean-
ingful decrease with treatment. Future clinical trials are
warranted, targeting pathologies with an underlying
leakiness of the gut, using disease-specific endpoints and
longer durations of the treatments. Given that we did
not observe synergism between GOS and the probiotic
strains, future trials should probably focus on single
components, or explore higher doses of GOS in synbio-
tic combinations.
Conclusion
This study provided an important test of the synbiotic
concept. The findings showed that autochthony of a bac-
terial strain is more important than the provision of pre-
biotic substrate at a 5-g dose for the establishment of a
probiotic in the human gut. This outcome is likely due to
the highly competitive environment that favors autoch-
thonous strains that possess traits that allow colonization
while effectively competing for substrates [53]. In addition,
although both the probiotic strains and the prebiotic GOS
improved barrier function, a combination of the two did
not result in apparent synergism. It is unclear how compe-
tition for the prebiotic can be avoided, but it is possible
that higher doses may be necessary. We selected the daily
amount of GOS in this study based on the dose that has
previously been shown to induce a bifidogenic effect [39],
which was confirmed in this study, and successfully enrich
the strain IVS-1 in humans [61]. However, for synbiotic
approaches, it might be necessary to give doses of
prebiotics that exceed those sufficient for bifidogenic ef-
fects to ensure that substrates are available for both the
resident microbiota and the incoming microbe. Accord-
ingly, in our previous study in rats, a GOS dose that was
approximately 30-fold higher when adjusted by body-
weight did result in clear synergism and increased compe-
tiveness of IVS-1 [61]. Although the synbiotic approach
tested in this study did not provide measurable synergism,
our findings clearly show that both probiotic strains and
the prebiotic improved markers of intestinal permeability.
Thus, this report provides a basis for the use of these
treatments (or combinations thereof) in pathologies with
an underlying leakiness of the gut.
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